[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR:

1991

CATEGORY:

Contraception (Birth Control) and Family Planning

TITLE

Phase II -- clinical trial with biodegradable subdermal contraceptive

implant Capronor (4.0-cm single implant)

AUTHORS

India. Indian Council of Medical Research [ICMR]. National Programme of

Research in Human Reproduction. Task Force on Hormonal Contraception

SOURCE

CONTRACEPTION. 1991 Oct;44(4):409-17.

ABSTRACT

The subdermal biodegradable contraceptive implant Capronor (4.0 cm) was implanted in 41 women to observe its

efficacy and side effects. Only 1 pregnancy was reported at 10 months of use and the life table continuation rate at

12 months was 82.2/100 users. No serious clinical side effects were reported during the study period. The

menstrual pattern was disrupted during the 1st 3 months of implant use in 2.3 of the women which improved by the

end of 12 months of use. The results of this phase II study suggest that Capronor is a safe and effective longacting

contraceptive These findings must be confirmed in a phase III clinical trial on a larger sample size. (author's)

(PubHealth.info Document ID: CONT3T 2010-06)

PubHealth.info NOTE: The author(s) of this article titled, "Phase II -- clinical trial with biodegradable subdermal

contraceptive implant Capronor (4.0-cm single implant)", is(are) India. Indian Council of Medical Research [ICMR].

National Programme of Research in Human Reproduction. Task Force on Hormonal Contraception. The source of

this article is "CONTRACEPTION. 1991 Oct;44(4):409-17.". This article was published in 1991 in English

language(s). (PubHealth.info® Document ID: CONT3T 2010-06. All rights reserved with PubHealth.info) PIN: 12010

This article is peer-reviewed.

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.